Washington State University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Washington State University sits in the top decile of US sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count).
Washington State University: 64 sponsored US clinical trials, 19 recruiting.
Washington State University sponsors 64 registered US clinical trials on ClinicalTrials.gov, 19 of them currently recruiting, and 40 completed. 1 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alcohol Use Disorder (AUD), with 3 trials.
Top-decile sponsor footprint
Washington State University ranks in the top decile of sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
40 of 40 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
64 total, page 1 of 2
TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)
NCT07171359
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
NCT07393672
Developing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery
NCT07052318
Impact of Cannabinoids on Menopause Symptoms
NCT06831916
FAmily Engagement Strategy for Coordinated Specialty Care
NCT06945055
Cognition After OSA Treatment Among Native American People (CATNAP)
NCT06227572
Acute Psychological and Physiological Effects of Cannabigerol
NCT06638996
Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach
NCT06693960
Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel
NCT06692933
Virtual Incentive Treatment for Alcohol
NCT06265506
Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
NCT06323837
Automated Reinforcement Management Systems, Phase II
NCT06456905
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
NCT06053411
Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints
NCT05846451
Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation
NCT05733442
Family Peer Navigator for Early Psychosis for Black Families
NCT05284721
Indian Transforming Alzheimer's Care Training (INTACT)
NCT06397339
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
NCT05181891
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
NCT05134857
Effective Caregiving for Neonatal Abstinence Syndrome: Testing an Instructional Mobile Technology Platform for High-Risk Pregnant Women
NCT04783558
Hyperbaric Oxygen Treatment (HBOT) During Methadone Tapering
NCT05924022
Caring Contacts: A Strength-based, Suicide Prevention Trial in 4 Native Communities
NCT02825771
Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance
NCT07494084
Acute Effects of Cannabis on Cognition and Affect
NCT07296874
Improving Activity in Adults With Chronic Pain With Online Resources
NCT06804239
Impact of Convenience on Whole Grain Consumption
NCT06160258
Empowered Relief Delivered by Nurses
NCT05934435
Acute Effects of Cannabis on Everyday Life Memory
NCT05488509
Colorectal Cancer Screening in Alaska Native Men
NCT06436300
Elderberry Consumption and Human Health
NCT06626373
The Ready-to-Eat Meals for Cardiovascular Health Study
NCT05472454
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
NCT05365451
Acute Effects of Cannabigerol
NCT05257044
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
NCT05081583
Elderberries and Obesity
NCT05723497
Automated Reinforcement Management System (ARMS)
NCT04656925
Improving Family Engagement in Coordinated Specialty Care for First Episode Psychosis
NCT04188366
Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study
NCT04656899
Promoting Risk Reduction Among Young Adults With Asthma During Wildfire Smoke Events (TRAK)
NCT04724733
Community-Engaged Options to Facilitate Opioid Reduction
NCT05098158
Naturalistic Monitoring and Treatment of Chronic Insomnia
NCT04013321
Phosphatidylethanol-Based Contingency Management for Housing
NCT04038021
Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product
NCT04392011
Barley Beta-glucan, Glycemic Control, and Appetite
NCT06146322
Technologically-Augmented Referrals to Mitigate Addiction Consequences
NCT04401215
Native-Changing High-risk Alcohol Use and Increasing Contraception Effectiveness Study
NCT03930342
Strong Men, Strong Communities Diabetes Risk Reduction in American Indian Men
NCT02953977
Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)
NCT03484364
Individualizing Incentives for Alcohol in the Severely Mentally Ill
NCT03481049
Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach
NCT03772262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Washington State University pipeline
19 recruiting of 64 indexed (30% open); 40 completed (63%).
Phase mix: 1 late (III/IV) vs 18 early (I/II) (early-phase heavy).
Top condition: Alcohol Use Disorder (AUD) (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Washington State University: open-pipeline peers nationwide
Peers matched on 64 registered trials and 30% open enrollment, not the therapeutic-area sidebar.
Washington State University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 64 trials (± recruiting share)
- Cephalon · 64 trials · 0% recruiting
- CooperVision · 64 trials · 3% recruiting
- NRG Oncology · 64 trials · 47% recruiting
- University of Houston · 64 trials · 20% recruiting
Sponsors near 30% open enrollment (± trial volume)
- Children's Hospital Los Angeles · 29% recruiting · 119 trials
- Natural Immune Systems · 29% recruiting · 17 trials
- Ono Pharmaceutical Co. · 29% recruiting · 17 trials
- Queen's Medical Center · 29% recruiting · 17 trials
Related
What to do with this Washington State University page
64 registered trials is a research-attention snapshot, not an endorsement of Washington State University or any single study.
- 19 of Washington State University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Alcohol Use Disorder (AUD) is the condition Washington State University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alcohol Use Disorder (AUD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Washington State University pipeline card: 64 registered trials from official public datasets.Report a data error.